US FDA's final rule on post-market reporting requirements for combination products is likely to be a welcome addition for industry.
The final rule, published Dec. 20, clarifies its scope, aims to minimize duplicative reporting, clarifies the definitions of certain terms...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?